News & Events
As a reminder, effective October 1, 2017, the 2018 ICD-10-CM updates are in effect (October 1, 2017 through September 30, 2018). Providers should be coding to the highest level of specificity per the 2018 ICD-10-CM updates. If an ICD code is entered that has been updated and/or now requires more specificity, suggestions for a more specific code will be displayed as shown below.
For More Information, CLICK HERE
On June 5, 2017, PathGroup’s clinical laboratory experienced an analytical event on one of the two general chemistry analyzers that caused a negative bias of calcium levels for those test processed on the affected instrument.
For more Information, CLICK HERE
In an ongoing effort to protect the privacy of our shared patients’ protected health information, PathGroup has strengthened our security measures. Beginning Monday,June 5, 2017, all PathGroup electronic client systems including PathConnect, PathGroup Mobile, Result Review, PathSupply and AutoPrint will have a new Single Sign-On system that will strengthen the authentication access. PathGroup’s new password procedures are required by all users.
For more information, please CLICK HERE
Beginning June 5, 2017, all PathGroup electronic client systems including PathConnect, PathGroup Mobile, Result Review, PathSupply and AutoPrint will have a new Single Sign-On system that will strengthen the authentication access. All users will need to comply with PathGroup’s password policies, including requiring users to reset passwords every 60 days.
For More Information CLICK HERE
Effective April 26, 2017 when completing an Advanced Beneficiary Notice (ABN) in PathConnect, the person responsible for collecting and submitting the ABN will now be prompted to provide a signature upon completion.
For more information, CLICK HERE
PathGroup is pleased to announce the release of SmartGenomics™ Complete, a pan cancer assay encompassing 160 cancer related genes, 126 gene fusions and whole genome copy number changes via cytogenomic array.
Also included in this major release are five new solid tumor disease specific profiles for use at diagnosis of various malignancies especially for metastatic, aggressive and/or high grade tumors in the following cancer types: Bladder, Breast, Gynecological (including ovarian carcinoma), Prostate and Sarcoma. Additionally, two new hematologic malignancy profiles have been introduced for myeloid neoplasms and lymphoid neoplasms respectively.
Existing SmartGenomics Profiles have also been improved to include the latest relevant assays such as PDL-1 for NSCLC, Her2 for colorectal cancer, gene fusions for thyroid carcinoma and neurological malignancies, copy number support for melanoma, plus other clinically supported additions. Additional information including the genes of interest, fusion partners and profile breakdowns are available by contacting Oncology Customer Support at OncologySupport@pathgroup.com.
Multiple benefits of high-throughput sequencing (commonly referred to as Next-Generation Sequencing or NGS) include: smaller input DNA requirements, greater sensitivity/specificity, advanced bioinformatics processing and rapid turn-around time.
Click HERE for more information.
Effective March 1, 2016, PathGroup will offer Informed Pregnancy Screen, a non-invasive prenatal screen (NIPS) that analyzes cell-free DNA (cfDNA) using next-generation sequencing to determine if a pregnancy is at increased risk for certain chromosome aneuploidies. Informed Pregnancy Screen has an industry-leading ‘no-call’ rate of 0.1% and a personalized positive predictive value (PPV) is included on every positive result. The test can be performed as early as 10 weeks gestation and results will be available in approximately 1 week. Electronic ordering and results delivery is available to PathGroup clients and post-test genetic counseling is available to patients if desired.
Click Here to read more.
This change will take effect on February 15, 2016
Effective February 15, 2016, PathGroup will be implementing the following procedure for all Urinalysis testing in an effort to improve the turnaround times as well as to better manage healthcare costs.
Click Here to read more.
January 4, 2016
PathGroup has been notified by our reference laboratory partner, ARUP Laboratories, of a resulting issue affecting specific send out testing that was processed through their facility. A compliance statement on results released from August 14, 2014 through November 13, 2015 was omitted while performing an interface coding change to the following tests:
The omission of the compliance statement did not affect the test result and all test results remain unchanged.
Click Here to read more.
PathGroup has been notified by our reference laboratory partner, ARUP Laboratories, that an incorrect unit of measure for Blood Urea Nitrogen (BUN) was reported using U/L instead of the correct unit of measure, mg/dL. BUN is a component of the FibroMeter assay (FIBROM) which ARUP Laboratories performs. Results were not affected by the associated incorrect unit of measure and all scores, classifications, and overall test result interpretations remain unchanged.
Click Here to read more.
